|
WO2016047769A1
|
|
Adjuvant obtained from layered double hydroxide
|
|
JP2014236748A
|
|
Recombinant polyvalent vaccine
|
|
JP2012080893A
|
|
Recombinant polyvalent vaccine
|
|
JP2009149650A
|
|
Japanese encephalitis virus antigen
|
|
JP2009278877A
|
|
Method for making animal model for postherpetic neuralgia
|
|
JP2009242367A
|
|
New vaccine containing mixed immunostimulator
|
|
KR20120098919A
|
|
Therapeutic agent for cancer
|
|
CN101626785A
|
|
Nerve elongation promoter and elongation inhibitor
|
|
KR20080036244A
|
|
Promoter for introducing a gene into a lymphocyte or blood cell and application thereof
|
|
CN101208106A
|
|
Cancer therapeutic agent
|
|
EP1840214A1
|
|
Attenuated chimeric flavivirus bearing attenuated japanese encephalitis virus gene as backbone
|
|
KR20080070012A
|
|
Recombinant polyvalent vaccine
|
|
CA2630770A1
|
|
Recombinant polyvalent vaccine
|
|
CN1981040A
|
|
Recombinant virus vector for gene introduction in lymphocyte
|
|
EP1721981A1
|
|
Recombinant varicella-zoster virus
|
|
JP2005097267A
|
|
New vaccine containing mucosa immunity-inducing adjuvant
|
|
EP1279735A1
|
|
Malaria plasmodium antigen polypeptide se36, method of purifying the same and vaccine and diagnostic with the use of the thus obtained antigen
|
|
CN1358101A
|
|
Method of controlling the qualities of attenuated pox vaccine
|
|
CN1306574A
|
|
Attenuated virus oka strain gene 62 and method for identifying virus strain for attenuated live vaccine by using same
|
|
AU4057899A
|
|
Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
|
